Rapport Therapeutics, Inc. Common Stock
Rapport Therapeutics, Inc. Common Stock (RAPP) Stock Ownership
Institutional vs insider vs public ownership from 13F and float data — top holders, activity, and insider trades below.
SEC 13F · FMP · RAPP · as of Sep 30, 2025
Ownership Breakdown
133
Institutional Holders
▲ 51 vs Q2
$1.46B
Total Inst. Value
▲ $1.03B vs Q2
36.50M
Shares Outstanding
freeFloat 47.84%
49.28M
13F Shares Held
▲ 10.78M vs Q2
Institutional ownership = 13F shares ÷ total outstanding. Insider % = 100 − free float. Public % = free float − institution %. Data: FMP /symbol-positions-summary + /shares-float + SEC EDGAR.
Top Institutional Holders
RAPP largest shareholders · institutional ownership
Q3 2025 · SEC 13F
Showing top 10 holders
| Holder | Shares | % Owned | Weight | Value | Reported | Change |
|---|---|---|---|---|---|---|
TRV GP V, LLC pharmaceutical preparations | 7.14M | 2.01% | 2.01% | $211.92B | Nov 13, 2025 | — held |
FMR LLC pharmaceutical preparations | 6.92M | 1.95% | 1.95% | $205.43B | Nov 13, 2025 | ▲ 1.44M |
ARCH VENTURE MANAGEMENT, LLC pharmaceutical preparations | 3.73M | 1.05% | 1.05% | $110.74B | Nov 14, 2025 | — held |
CAPITAL INTERNATIONAL INVESTORS pharmaceutical preparations | 3.40M | 96.00% | 96.00% | $101.06B | Nov 13, 2025 | ▲ 800.0K |
CORMORANT ASSET MANAGEMENT, LP pharmaceutical preparations | 3.19M | 90.07% | 90.07% | $94.82B | Nov 14, 2025 | ▲ 251.6K |
GOLDMAN SACHS GROUP INC pharmaceutical preparations | 2.42M | 68.33% | 68.33% | $71.93B | Nov 14, 2025 | ▲ 1.19M |
SOFINNOVA INVESTMENTS, INC. pharmaceutical preparations | 1.95M | 54.95% | 54.95% | $57.84B | Nov 14, 2025 | ▼ 48.0K |
JOHNSON & JOHNSON pharmaceutical preparations | 1.78M | 50.35% | 50.35% | $53.00B | Mar 18, 2026 | ▼ 713.5K |
VANGUARD GROUP INC pharmaceutical preparations | 1.63M | 45.89% | 45.89% | $48.31B | Nov 7, 2025 | ▲ 519.0K |
BLACKROCK, INC. pharmaceutical preparations | 1.57M | 44.24% | 44.24% | $46.57B | Nov 12, 2025 | ▲ 348.9K |
Data from SEC Form 13F filings. Ownership bar normalised to largest holder. Change flags: isNew / isSoldOut / changeInSharesNumber (FMP extract-analytics/holder).
Institutional Activity
Q3 2025 vs prior quarter
Q3 2025
18
Increased
+8.02M shares22
New Positions
first time holders6
Decreased
−1.56M shares0
Sold Out
fully exitedNet shares change (top 50)
+6.46M
+8.02M / −1.56M
Net new holders
+34
22 new / 0 exited
Based on top 50 institutional holders by position size. Fields: isNew, isSoldOut, changeInSharesNumber (FMP extract-analytics/holder, limit=50).
Insider Buying vs Selling
RAPP insider trading · insider activity
Source: SEC Form 4
Insiders have been primarily selling shares recently. Selling may be driven by pre-scheduled Rule 10b5-1 plans rather than negative sentiment.
0
Buy transactions
10
Sell transactions
0.00
Buy/Sell ratio
$1M
Total disposed
Recent Insider Transactions
Showing 10 most recent · Common Stock only
| Name · Role | Date | Type | Shares | Price | Value | After Trans. | Filing |
|---|---|---|---|---|---|---|---|
Third Rock Ventures V, L.P. 10 percent owner | May 26, 2026 | Sale | 18,572 | $40.05 | $743.8K | 6.28M | Form 4 ↗ |
Third Rock Ventures V, L.P. 10 percent owner | May 11, 2026 | Sale | 133,618 | $40.24 | $5.38M | 6.30M | Form 4 ↗ |
Third Rock Ventures V, L.P. 10 percent owner | May 7, 2026 | Sale | 271,495 | $40.12 | $10.89M | 6.44M | Form 4 ↗ |
Third Rock Ventures V, L.P. 10 percent owner | May 8, 2026 | Sale | 5,018 | $40.31 | $202.3K | 6.43M | Form 4 ↗ |
Third Rock Ventures V, L.P. 10 percent owner | Apr 17, 2026 | Sale | 426,005 | $40.32 | $17.18M | 6.71M | Form 4 ↗ |
Yeleswaram Krishnaswamy Chief Development Officer | Apr 17, 2026 | Sale | 20,225 | $39.99 | $808.8K | 246.4K | Form 4 ↗ |
Yeleswaram Krishnaswamy Chief Development Officer | Apr 10, 2026 | Sale | 500 | $34.98 | $17.5K | 286.0K | Form 4 ↗ |
Yeleswaram Krishnaswamy Chief Development Officer | Apr 13, 2026 | Sale | 9,165 | $34.97 | $320.5K | 276.9K | Form 4 ↗ |
Yeleswaram Krishnaswamy Chief Development Officer | Apr 14, 2026 | Sale | 10,200 | $35.08 | $357.8K | 266.7K | Form 4 ↗ |
Yeleswaram Krishnaswamy Chief Development Officer | Apr 8, 2026 | Sale | 360 | $34.90 | $12.6K | 286.5K | Form 4 ↗ |
Source: /insider-trading/search (FMP stable). Buy/Sell direction: acquisitionOrDisposition A=Buy, D=Sell. RSU vesting (M-Exempt) excluded from sentiment bar. All data from SEC EDGAR public filings.
About institutional & insider ownership
Rapport Therapeutics, Inc. Common Stock (RAPP) is primarily owned by institutional investors, who hold approximately 100.0% of total shares outstanding. Company insiders own approximately 52.16%, while retail and public investors account for the remaining 0.00%.
The largest institutional shareholder of Rapport Therapeutics, Inc. Common Stock is TRV GP V, LLC, holding approximately 7.14 million shares — equal to 2.01% of outstanding shares — as of September 30, 2025.
A total of 133 institutional investors currently hold RAPP stock, with a combined institutional value of approximately $1.46 billion as of the most recent 13F filing period.
Frequently asked questions
RAPP ownershipRapport Therapeutics, Inc. Common Stock (RAPP) is primarily owned by institutional investors, who hold approximately 100.0% of shares. The largest shareholder is TRV GP V, LLC with a 2.01% stake. Company insiders hold 52.16%. Data sourced from SEC Form 13F as of September 30, 2025.